Eckhard von Keutz, PhD Appointed to the Phenovista Scientific Advisory Board

Eckhard von Keutz PhD

Phenovista, a life sciences services company developing and implementing multiplexed, high content imaging-based phenotypic assays for target validation, lead optimization, and mechanism of action studies, today announced the appointment of Eckhard von Keutz to its Scientific Advisory Board. Most recently, Dr. von Keutz served as the Senior Vice President and Head of Translational Science (Preclinical and Early Clinical Development) at Bayer Pharmaceuticals.

James Evans, PhD, Chief Executive Officer of Phenovista

“We are excited to welcome Eckhard to our Scientific Advisory Board. His guidance will be invaluable as continue to deliver high-quality data and unprecedented biological insights to our biopharmaceutical clients, enabling them to more confidently answer complex discovery and development questions and make more informed decisions about development candidates.”

Dr. Eckhard von Keutz has extensive experience in designing and conducting preclinical/toxicological studies, and toxicological risk assessment and management. In addition to serving as Senior Vice President and Head of Translational Science, his past roles at Bayer included Senior Vice President and Global Head of Early Development, Vice President and Global Head of Healthcare Toxicology, Senior Director and Global Head of Toxicology-Pharma, and Scientific Coordinator of the company’s Toxicology Institute.

“Phenovista’s ability to support and de-risk mission-critical R&D decision-making is unmatched in the industry,” said Dr. von Keutz. “There are significant advantages delivered by their high-plex phenotypic assays as compared to conventional, low-plex in vitro assays throughout the R&D workflow. These advantages are particularly important in toxicological risk assessment as these models have the potential to provide data with increased predictive value and offset the use of in vivo approaches by the biopharmaceutical industry.”

Phenovista develops and offers off-the-shelf and custom phenotypic assays to support a range of R&D activities including toxicology. Toxicological assays include those to assess mitochondrial health, cell viability and cell proliferation. Cell painting assay services in the areas of liver and cardiotoxicity are also available and provide detailed information for compound profiling.

Other Executives In the News

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Executives on the Move

Dr. Val Kolesnitchenko brings extensive ophthalmology experience in clinical practice and industry to new therapeutics for the aging eye.
These strategic appointments signify a significant milestone for BRIJ Medical as they usher in a new era of post-surgical and trauma incision care with proven technologies that minimize wound complications and scarring.
David Kroekel has more than 35 years of experience in medical device, combination product operations, and product development.
Dr. Konstantin Kousoulas, a leading virologist will work to further Rational Vaccines core mission of eradicating the world of the herpes simplex virus. "Dr. Kousoulas...
Shannon Allen expertise lies in establishing dynamic processes and teams that are committed to superior delivery, creating value and spurring adoption of key solutions.

By using this website you agree to accept Medical Device News Magazine Privacy Policy